Pancreatic cancer is an increasingly lethal cancer and is often diagnosed at an advanced stage. Pancreatic ductal adenocarcinoma (PDAC) accounts for more than 90% of all pancreatic malignant tumors and is known as the "king of cancers". The degree of malignancy is very high, making diagnosis and treatment difficult. This is because pancreatic ductal adenocarcinoma tissue contains a large amount of fibrous tissue in addition to ductal epithelial cell components. The existence of fibrous tissue results in poor blood supply for pancreatic cancer, making it difficult for chemotherapy drugs to enter, so the treatment effect is not ideal. So there is a need to develop new and more effective treatments to cure this disease.
Pancreatic Cancer Antibodies We Offer
Antibodies can be used to target cancer cells and prevent tumor growth and progression. Antibodies have been widely used in malignant tumor research, such as pancreatic cancer, breast cancer, colon cancer, non-small cell lung cancer, etc. Clinical studies have shown that antibody therapy can not only effectively kill focus cells, but also activate the human immune system to improve the body's defense against cancer, while reducing treatment side effects and improving patient survival rates. The essence of antibody therapy is to use specific monoclonal antibodies synthesized in vitro to achieve the purpose of treatment by identifying, binding and eliminating disease-related antigens or disease cells expressing antigens. Alfa Cytology has extensive experience in pancreatic cancer research and can provide you with antibody products suitable for your research project.
Alfa Cytology is committed to providing customers with antibody products with strong targeting, high stability, and obvious effects for pancreatic cancer research. We can recommend the best antibody options based on our customers' needs. If you are interested in our products, please contact us for more details.
MA242
Catalog No.: PC0062
Description: MA242 is a specific dual inhibitor of MDM2 and NFAT1. MA242 directly binds MDM2 and NFAT1 with high affinity, induces their protein degradation, and inhibits NFAT1-mediated MDM2 transcription. MA242 induces apoptosis in pancreatic cancer cell lines regardless of p53 status.
KRAS inhibitor-13
Catalog No.: PC0063
Description: KRAS inhibitor-13 is a potent KRAS G12C inhibitor with an IC50 of 0.883 µM. KRAS inhibitor-13 exhibits p-ERK inhibitory activity in MIA PaCA-2 and A549 cells, with IC50 of 5.9 and >100 µM respectively. KRAS inhibitor 13 has the potential to study pancreatic, colorectal, and lung cancer.
FX-11
Catalog No.: PC0064
Description: FX-11 is a potent, selective, reversible, competitive inhibitor of lactate dehydrogenase A (LDHA) with a Ki of 8 μM. FX-11 reduces ATP levels and induces oxidative stress, ROS production, and cell death. FX-11 shows antitumor activity in lymphoma and pancreatic cancer xenografts.
KRAS inhibitor-12
Catalog No.: PC0065
Description: KRAS inhibitor-12 is a potent KRAS G12C inhibitor with an IC50 of 0.537 µM. KRAS inhibitor-12 exhibits p-ERK inhibitory activity in MIA PaCA-2 and A549 cells with IC50 of 1.3 and 3.7 µM, respectively. KRAS inhibitor 12 has the potential to be studied in pancreatic, colorectal, and lung cancers.
KRAS inhibitor-14
Catalog No.: PC0066
Description: KRAS inhibitor-14 is a potent KRAS G12C inhibitor. KRAS inhibitor-14 exhibits p-ERK inhibitory activity in MIA PaCA-2 and A549 cells, with IC50 of 1.12 and >33.3 µM respectively. KRAS inhibitor-14 has the potential to study pancreatic, colorectal, and lung cancer.
KRAS inhibitor-15
Catalog No.: PC0067
Description: KRAS inhibitor-15 is a potent KRAS G12C inhibitor with an IC50 of 0.954 µM. KRAS inhibitor-15 exhibits p-ERK inhibitory activity in MIA PaCA-2 and A549 cells, with IC50 of 2.03 and >33.3 µM respectively. KRAS inhibitor-15 has the potential to study pancreatic, colorectal and lung cancers.
KRAS inhibitor-16
Catalog No.: PC0068
Description: KRAS inhibitor-16 is a potent KRAS G12C inhibitor with an IC50 of 0.457 µM. KRAS inhibitor-16 showed p-ERK inhibitory activity in MIA PaCA-2 and A549 cells, with IC50 of 3.06 and 11.1 µM respectively. KRAS inhibitor-16 has the potential to study pancreatic, colorectal, and lung cancer.
KRAS inhibitor-17
Catalog No.: PC0069
Description: KRAS inhibitor-17 is a potent KRAS G12C inhibitor with an IC50 of 3.37 µM. KRAS inhibitor-17 exhibits p-ERK inhibitory activity in MIA PaCA-2 and A549 cells, with IC50 of 9.25 and >33.3 µM respectively. KRAS inhibitor-17 has the potential to study pancreatic, colorectal, and lung cancers.
KRAS inhibitor-18
Catalog No.: PC0070
Description: KRAS inhibitor-18 is a potent KRAS G12C inhibitor. KRAS inhibitor-18 exhibits p-ERK inhibitory activity in MIA PaCA-2 and A549 cells with IC50 of 66.4 and 11.1 µM, respectively. KRAS inhibitor-18 has the potential to study pancreatic, colorectal, and lung cancer.
OICR-9429
Catalog No.: PC0071
Description: OICR-9429 is a high-affinity WD repeat domain 5 inhibitor that competitively blocks the interaction of WDR5 with MLL proteins by binding to the central peptide-binding pocket of WDR5. OICR-9429 can inhibit histone H3K4 trimethylation and can be used to study a variety of cancers, including non-MLL rearranged leukemia, colon cancer, pancreatic cancer, prostate cancer and bladder cancer.
MA242 free base
Catalog No.: PC0072
Description: MA242 free base is a specific dual inhibitor of MDM2 and NFAT1. MA242 free base binds directly to MDM2 and NFAT1 with high affinity, induces their protein degradation, and inhibits NFAT1-mediated MDM2 transcription. MA242 freebase induces apoptosis in pancreatic cancer cell lines regardless of p53 status.
6-Diazo-5-oxo-L-nor-Leucine
Catalog No.: PC0073
Description: 6-Diazo-5-oxo-L-nor-Leucine is a glutamine antagonist that irreversibly inhibits glutamine catabolism. 6-Diazo-5-oxo-L-nor-Leucine shows good anticancer activity (especially in pancreatic cancer) and reduces the self-renewal potential and metastatic ability of tumor cells. 6-Diazo-5-oxo-L-nor-Leucine also has antibacterial and antiviral activity.
Zamaporvint
Catalog No.: PC0074
Description: Zamaporvint is an orally active, selective Wnt inhibitor. Zamaporvint targets the membrane-bound ortho-acyltransferase Porcupine and inhibits Wnt ligand palmitoylation, secretion, and pathway activation. Zamaporvint displays favorable pharmacokinetic profiles and potent antiproliferative effects in Wnt ligand-dependent colorectal and pancreatic cell lines.
SANT 2
Catalog No.: PC0075
Description: SANT 2 is a potent antagonist of the Hh signaling pathway. Hedgehog (Hh) signaling plays an important role in cell signaling in embryonic development and adult tissue homeostasis. SANT 2 has the potential to study a variety of malignancies, including Gorlin syndrome, prostate, pancreatic, and breast cancer.
Nidanilimab
Catalog No.: PC0076
Description: Nidanilimab (CAN04) is a fully humanized monoclonal anti-IL1RAP antibody. Nidanilimab blocks IL1α and IL1β signaling and stimulates the immune system to destroy tumor cells. Nidanilimab can be used in the research of non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC).
KRAS G12C inhibitor 47
Catalog No.: PC0077
Description: KRAS G12C inhibitor 47 is a potent KRAS G12C inhibitor. KRAS G12C inhibitor 47 showed p-ERK inhibitory activity in MIA PaCA-2 and A549 cells with IC50 of 0.046 and 69.8 µM, respectively. KRAS G12C inhibitor 47 has the potential to be studied in pancreatic, colorectal, and lung cancers.
Benzyl-α-GalNAc
Catalog No.: PC0078
Description: Benzyl-α-GalNAc is a potent O-glycosylation inhibitor. Benzyl-α-GalNAc effectively inhibits the proliferation and activation of LX-2 cells and inhibits the expression of type I/III collagen, showing good potential in liver fibrosis research. Benzyl-α-GalNAc also significantly enhances the antitumor activity of 5-FU (HY-90006) (e.g., pancreatic cancer) by inhibiting O-glycosylation.
DX3-213B
Catalog No.: PC0079
Description: DX3-213B is a highly potent, orally active oxidative phosphorylation complex I inhibitor (IC50=3.6 nM). DX3-213B impairs ATP production and prevents MIA PaCa-2 cell growth. DX3-213B is used in pancreatic cancer research.
EIPA hydrochloride
Catalog No.: PC0080
Description: EIPA hydrochloride is an orally active TRPP3 channel inhibitor with an IC50 of 10.5 μM. EIPA hydrochloride also enhances autophagy by inhibiting NHE3. EIPA hydrochloride also inhibits macropinocytosis. EIPA hydrochloride can be used for research on inflammation and cancer, such as gastric cancer, colon cancer, and pancreatic cancer.
PARP1/BRD4-IN-1
Catalog No.: PC0081
Description: PARP1/BRD4-IN-1 is a potent and highly selective PARP1/BRD4 inhibitor. PARP1/BRD4-IN-1 inhibits the expression and activity of PARP1 and BRD4, and synergistically inhibits the malignant growth of pancreatic cancer cells.
